Sudden death during a change in treatment for pulmonary hypertension.
We describe an infant with an atrioventricular septal defect and separate valvar orifices for the right and left ventricles, the so-called primum defect, who presented with serious pulmonary hypertension. Treatment with sildenafil was changed to intravenous epoprostenol due to lack of any measurable effects of the initial therapy as shown by echocardiography. The girl died three days after the change in treatment. We suggest that a mismatch between ventilation and perfusion contributed significantly to her death.
Brun
Henrik
H
Department of Paediatrics, National Hospital (Rikshospitalet), 0027 Oslo, Norway. henrik.brun@riskhospitalet.no
Holmström
Henrik
H
Thaulow
Erik
E
D003645:Death, Sudden / Q000209:etiology*; D011464:Epoprostenol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007223:Infant; D014665:Vasodilator Agents / Q000009:adverse effects*
D014665:Vasodilator Agents; D011464:Epoprostenol